Atrys Health SA (ATRY) AI Stock Analysis

• Market Cap: €220.34M
• Dividend Yield: N/A
• Average Volume (3M): 69.85K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.59
• Revenue Growth: 5.54%
• EPS Growth: 30.33%
• Country: ES
• Employees: 1,637
• Sector: Healthcare
• Sector Strength: 37
• Industry: Biotechnology
• EPS (TTM): -0.42
• Shares Outstanding: 76,014,190
• 10 Day Avg. Volume: 73,023
• 30 Day Avg. Volume: 69,852
• PEG Ratio: 0.86
• Price to Book (P/B): 1.25
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -13.82
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: €3.75
• Price Target Upside: 29.31% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2

• Rating: 49 Neutral
• Price Target: €3.00 ▲(3.45%Upside)

The overall stock score of Atrys Health SA is primarily impacted by financial performance challenges, particularly in profitability and liquidity. Technical indicators provide mixed signals, with short-term bullish trends but longer-term bearish outlooks. Valuation remains a concern due to negative earnings and lack of dividends.

Atrys Health SA Business Overview & Revenue Model

Company Description

Atrys Health SA (ATRY) is a Spanish company that operates in the healthcare sector, primarily focusing on providing precision medicine services, diagnostic imaging, and innovative treatment solutions. The company leverages advanced technologies and specialized medical expertise to offer a range of healthcare services aimed at improving patient outcomes. Its core offerings include telemedicine, radiotherapy, and pathology services, catering to both national and international markets.

How the Company Makes Money

Atrys Health SA generates revenue through its diverse range of healthcare services, primarily focusing on precision medicine and diagnostic imaging. The company earns money by providing telemedicine consultations, where patients can receive medical advice and services remotely. Additionally, Atrys Health offers diagnostic imaging services, such as MRI and CT scans, which are essential for accurate diagnoses and treatment planning. Another significant revenue stream comes from its radiotherapy services, which are used for cancer treatment. The company also collaborates with hospitals and healthcare institutions, establishing partnerships that enhance its service offerings and expand its market reach, contributing to its earnings.

Atrys Health SA Financial Statement Overview

Summary

Atrys Health SA shows strong revenue growth but is facing significant profitability and liquidity challenges. The company has a strong gross profit margin, but negative net income and free cash flow indicate ongoing financial issues. The balance sheet reflects moderate leverage but increasing liabilities, necessitating strategic adjustments.

Income Statement

Atrys Health SA has shown consistent revenue growth, with a 5.55% increase from 2023 to 2024. However, profitability metrics are concerning with a negative EBIT and net income indicating ongoing operational challenges. The gross profit margin remains strong at 68.36% for 2024, but the net profit margin is negative due to substantial net losses.

Balance Sheet

The company maintains a moderate debt-to-equity ratio of 0.66 in 2024, reflecting reasonable leverage for the biotechnology industry. However, a declining equity ratio from 46.06% in 2023 to 43.32% in 2024 indicates increasing liabilities relative to assets. Return on equity is negative, highlighting profitability issues.

Cash Flow

Operating cash flow has improved to a positive $2.997 million in 2024, but free cash flow remains negative, indicating ongoing capital expenditure demands. The operating cash flow to net income ratio is not meaningful due to negative net income, and free cash flow growth remains negative, pointing to liquidity challenges.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	212.74M	201.57M	186.99M	121.01M	31.40M
Gross Profit	145.38M	141.77M	154.51M	100.89M	24.25M
EBITDA	19.07M	31.91M	16.63M	5.87M	4.81M
Net Income	-31.77M	-45.59M	-23.47M	-23.20M	―
Balance Sheet
Total Assets	584.19M	629.00M	705.28M	565.63M	175.78M
Cash, Cash Equivalents and Short-Term Investments	29.29M	42.18M	35.84M	40.57M	17.60M
Total Debt	166.13M	254.00M	258.74M	204.51M	71.46M
Total Liabilities	330.95M	339.12M	367.71M	291.65M	100.45M
Stockholders Equity	253.10M	289.87M	337.63M	274.03M	75.33M
Cash Flow
Free Cash Flow	-10.14M	-14.24M	-30.59M	-3.87M	―
Operating Cash Flow	3.00M	-1.09M	-15.43M	4.69M	―
Investing Cash Flow	-12.95M	395.00K	-80.59M	-2.45M	―
Financing Cash Flow	-11.51M	8.19M	94.77M	14.08M	62.63M

Atrys Health SA Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 2.90
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ES:ATRY, the sentiment is Positive. The current price of 2.9 is above the 20-day moving average (MA) of 2.65, above the 50-day MA of 2.75, and below the 200-day MA of 3.13, indicating a neutral trend. The MACD of 0.02 indicates Negative momentum. The RSI at 67.25 is Neutral, neither overbought nor oversold. The STOCH value of 89.08 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ES:ATRY.

Atrys Health SA Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	66 Neutral	€1.84B	34.97	10.52%	2.33%	7.10%	103.68%
RJF	66 Neutral	€245.01M	22.19	5.11%	1.40%	5.10%	20.61%
ORY	57 Neutral	€218.20M	―	-5.48%	―	―	-36.82%
ATRY	49 Neutral	€220.34M	―	-11.64%	―	5.54%	30.33%

Atrys Health SA Corporate Events

Atrys Health Announces Board of Directors Changes

Atrys Health, S.A. has announced changes to its board of directors following the recent Ordinary General Shareholders’ Meeting. Key changes include the election of Ms. María Antonia Isach Gabaldón as an executive director and the re-election of Mr. Santiago de Torres Sanahuja and Ms. Isabel Lozano Fernández as directors. Additionally, Mr. Jaime del Barrio Seoane has resigned due to new professional commitments. These changes are likely to impact the company’s strategic direction and governance, potentially influencing its market positioning and stakeholder relations.

The most recent analyst rating on (ES:ATRY) stock is a Buy with a EUR5.00 price target. To see the full list of analyst forecasts on Atrys Health SA stock, see the ES:ATRY Stock Forecast page.

Atrys Health Announces CEO Succession Plan and Reports Q1 2025 Growth

Atrys Health SA has announced a succession plan involving the appointment of Marian Isach as the future CEO, succeeding Isabel Lozano, who will remain as a non-executive director. Santiago de Torres will transition to a non-executive chairman role. This plan reflects Atrys’ commitment to internal talent and governance best practices. The company also reported an 11.2% increase in revenue for the first quarter of 2025, driven by growth across all business areas, particularly in Oncology and Diagnosis.

Atrys Health SA Reports Q1 2025 Results with Strategic Growth Focus

Atrys Health SA released its first quarter 2025 results, highlighting its strategic focus on expanding its customer base and business lines. The announcement underscores the company’s commitment to growth and market share enhancement, although it acknowledges potential risks and uncertainties that could impact future performance.

Atrys Health Calls for Ordinary General Shareholders’ Meeting

Atrys Health S.A. has announced the convening of its Ordinary General Shareholders’ Meeting to be held on June 12, 2025, with a second call on June 13, 2025, in Madrid. The agenda includes the approval of annual accounts, re-election of KPMG as auditors, appointment and re-election of directors, and modifications to the remuneration policy for directors. These decisions are crucial for the company’s governance and financial oversight, impacting stakeholders by ensuring transparency and continuity in leadership.

Atrys Announces Leadership Succession and Reports Strong Revenue Growth

Atrys Health SA has announced a leadership succession plan, with Marian Isach set to become the new CEO, replacing Isabel Lozano, who will transition to a non-executive director role. Santiago de Torres will shift from executive to non-executive chairman. This move is part of a broader generational change strategy initiated in 2024, aimed at promoting internal talent and ensuring continuity in the company’s leadership model. The company also reported an 11.2% revenue increase in the first quarter of 2025, driven by growth across all business areas, particularly in Oncology and Diagnosis, highlighting Atrys’ ongoing expansion and market strength.

Atrys Health Announces Q1 2025 Results Webcast

Atrys Health, S.A. has announced a webcast for analysts and investors to present its first quarter 2025 results, scheduled for May 7, 2025. This event, featuring CEO Isabel Lozano and CFO José María Huch, is part of Atrys’ ongoing efforts to maintain transparency with stakeholders and could impact investor confidence and market positioning.